[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641405":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":26,"responsibleParty":36,"collaborators":26,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":26,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":26,"enrollmentInfo":49,"targetDuration":26,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":26,"overallStatus":58,"whyStopped":26,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":26},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"rhTPO+CsA","EXPERIMENTAL","rhTPO 300U\u002Fkg\u002Fd, CsA 3-5mg\u002Fkg\u002Fd",[13,14],"Drug: rhTPO","Drug: Cyclosporine (CsA)",{"label":16,"type":17,"description":18,"interventionNames":19},"CsA","ACTIVE_COMPARATOR","CsA 3-5mg\u002Fkg\u002Fd",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","rhTPO","rhTPO 300U\u002Fkg\u002Fd, subcutaneous injection, once a month for 14 consecutive days",[9],null,{"type":22,"name":28,"description":18,"armGroupLabels":29,"otherNames":26},"Cyclosporine (CsA)",[16,9],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Bing Han, Doctor","CONTACT","+86 13601059938","hanbing_li@sina.com.cn",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Bing Han","Professor","100641405","phase-3-rhtpo--csa-vs-csa-in-the-treatment-of-lr-mds-with-thrombocytopenia-100641405",false,"NCT07653581","rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia","rhTPO + CsA Versus CsA Alone in the Treatment of Lower-risk MDS With Thrombocytopenia: a Single-center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Confirmed diagnosis of lower-risk MDS;\n3. Platelet ≤ 30×109\u002FL, or \\\u003C 50×109\u002FL and accompanied by bleeding events;\n4. Baseline liver and kidney functions \\\u003C2 ULN;\n5. Signed the informed consent form;\n6. ECOG 0-2;\n\nExclusion Criteria:\n\n1. History of leukemia or stem cell transplantation, treatment-related MDS or malignant tumors;\n2. With splenomegaly or myelofibrosis;\n3. Infections or bleeding that cannot be controlled by standard treatment;\n4. Any concurrent malignant tumors within the past 5 years, or basal cell carcinoma of the skin at the local site;\n5. History of thromboembolic events, heart attack or stroke and current use of anticoagulants;\n6. Previously received cyclosporine (CsA) or ATG within 6 months;\n7. Previously used IL-11, rhTPO or TPO-RA;\n8. Pregnant or lactating women;\n9. Participated in other clinical trials within 3 months.","ALL","18 Years",{"count":50,"type":51},78,"ESTIMATED","INTERVENTIONAL",[54],"PHASE3","This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.",[57],"Lower-risk Myelodysplastic Syndromes","NOT_YET_RECRUITING","2026-06-11",{"date":61,"type":62},"2026-06-17","ACTUAL",{"date":64,"type":51},"2026-06",{"date":66,"type":51},"2029-12",{"name":5,"class":6}]